Lexogen and OnRamp Bioinformatics partner to provide differential gene expression data analysis and interpretation for QuantSeq 3' mRNA-Seq users

Lexogen | June 17, 2020

Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND™, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowledge bases. Lexogen's QuantSeq 3' mRNA-Seq is a straightforward, fast, and cost-efficient method for library preparation. It has been widely used for expression profiling analysis and is currently featured in more than 470 publications. "QuantSeq is a well-established library preparation kit, validated by researchers who have used it for a broad range of applications. We are continuously enhancing the workflow based on the user feedback, and offering a complete solution including data analysis has always been top priority", said Dalia Daujotyte, Chief Commercial Officer at Lexogen. As a platform for scientists, ROSALIND empowers QuantSeq 3' customers to analyze, interpret and collaborate globally on differential gene expression analysis without the need for specialized bioinformatics or programming skills. "Through our collaborations, it is our goal to provide full transcriptome analysis solutions vetted by experts in their fields. Access to QuantSeq data processing on ROSALIND not only gives an opportunity to an in-depth gene expression analysis, but also enables collaboration and multi-omics work without leaving the environment", added Daujotyte.

Spotlight

Graeme Pallas is a Recruitment Consultant at CK Science working closely with both candidates and companies operating in the biotechnology sector. He is often asked about progression opportunities in production. In this video he talks about what opportunities are available and how to progress.

Spotlight

Graeme Pallas is a Recruitment Consultant at CK Science working closely with both candidates and companies operating in the biotechnology sector. He is often asked about progression opportunities in production. In this video he talks about what opportunities are available and how to progress.

Related News

Yufan Biotechnologies and Abound Bio Sign Multi-Year Agreement to Develop Next Generation CAR T-cell Therapies for Cancer

Yufan Biotechnologies | September 17, 2020

Exhaustion of T-cells is a key reason why CAR T-cell therapy may fail to control cancer. Recent work led by Xuebin Liao, PhD, Professor of Pharmaceutical Science at Tsinghua University (Si et al., Cancer Cell 2020) shows that HPK1 (hematopoietic progenitor kinase 1) promotes T cell exhaustion via NFkB-Blimp1 activation and that blocking HPK1, either by gene knockout or by small-molecule inhibitors, is an attractive strategy to improve CAR T-cell immunotherapy. These innovative approaches are being evaluated clinically by Yufan Biotechnologies, co-founded by Professor Liao and Yan Zhang, CEO. Yufan Biotechnologies has now partnered with Abound Bio, Inc, a life sciences company with world-renowned expertise in finding antibodies to direct CAR T-cells against cancer targets. Abound Bio was co-founded by Dimiter Dimitrov, PhD, and John Mellors, MD, CEO. The three-year partnership covers the incorporation of antibodies to novel cancer targets into the enhanced, HPK1-inhibited CAR T-cell platform.

Read More

MEDICAL

PhageNova Bio, Inc. Announces Publication Describing New Method for Safe and Effective Pulmonary Delivery of Therapeutics

PhageNova Bio, Inc. | December 14, 2020

PhageNova Bio, Inc. ("PhageNova") is pleased to declare the distribution of information created through a sponsored research agreement with Rutgers, The State University of New Jersey. The Med (a Cell Press distribution) article, entitled Targeted Phage Display-Based Pulmonary Vaccination in Mice and Non-human Primates, portrays another technique for protected and effective pulmonary delivery of therapeutics, including an aerosol vaccination strategy which is being developed to address the current SARS-CoV-2 pandemic. "Our targeted method of pulmonary delivery is the initial step towards the development of aerosol phage-based vaccines for human applications against multiple diseases," says Renata Pasqualini, PhD, co-senior study author, Founder and Chief Scientific Officer of PhageNova, and Chief of the Division of Cancer Biology, Department of Radiation Oncology at Rutgers Cancer Institute and Rutgers New Jersey Medical School. "Other advantages of phage particles are that they are highly stable under harsh environmental conditions, and their large-scale production is extremely cost-effective compared with other vaccine strategies because they don't need to be refrigerated, which is a particularly important requirement for the developing world."

Read More

CELL AND GENE THERAPY

Tevard Biosciences and Zogenix Collaborates to Identify and Develop Novel tRNA-based Gene Therapies for Dravet Syndrome and other Genetic Epilepsies

Tevard Biosciences | December 04, 2020

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platforms focused with respect to mRNA Stabilization and Nonsense Codon Suppression to find and advance novel drug candidates for the treatment of Dravet condition and other genetic epilepsies. Zogenix will additionally build up the up-and-comers through cutting edge preclinical examinations and clinical turn of events, and be responsible for overall commercialization.

Read More